Matrix metalloproteinase-9 and monocyte chemotactic protein-1 in patients with bronchial asthma combined with type 2 diabetes mellitus
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Objective: to study the content of MMP-9 and MCP-1 in patients with exacerbation of bronchial asthma combined with type 2 diabetes mellitus and exacerbation of bronchial asthma without of comorbid DM. Materials and methods: 70 patients with moderate exacerbations of bronchial asthma (BA), including 36 patients with BA combined with type 2 diabetes mellitus (T2DM) (group I) and 34 patients with BA exacerbations without DM (group II), aged 38.8±2.7 years were observed. All patients had their serum and exhaled air condensate (EAC) concentrations of matrix metalloproteinase-9 (MMP-9) and monocyte chemotactic protein (MCP)-1 measured by enzyme-linked immunosorbent assay, as well as their monocyte phagocytic activity measured by the spontaneous test with nitroblue tetrazolium (NBT- test), phagocytic index (PI), and phagocytic number (PN). Results: in patients of Group I, the concentrations of MMP-9 and MCP-1 in the blood serum exceeded those in Group II and the control group, as well as those in the ACE. The detected correlations between the studied indicators, between each indicator and the FEV₁ and HbA 1 C levels, indicated their close relationship with each other in the exacerbation of BA combined with T2DM, and the negative impact of type 2 DM on the indicators. The results of the NBT-test in patients of groups I and II did not differ significantly, but were 1.5 times (p
Fields of Study & Subjects
Asthma and respiratory diseases
Chronic Obstructive Pulmonary Disease (COPD) Research
Adipokines
Inflammation
and Metabolic Diseases
Publication details
- Journal / source
- South Russian Journal of Therapeutic Practice
- Volume
- 7
- Issue
- 1
- Pages
- 79–86
- Publication date
- 27 March 2026
- Language
- EN